Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early dapagliflozin after acute coronary syndrome in type 2 diabetes
IRCT20250302064896N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dapagliflozin in acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Improvement of left atrial function, Left atrial volume and 1 more. Started Apr 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
acute coronary syndrome (ACS)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20250302064896N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250302064896N1.